Want to see BRTX full AI Analyst Report?
BRTX Stock Chart & Stats
$1.18
-$0.13(-7.22%)
At close: 4:00 PM EST
$1.18
-$0.13(-7.22%)
Day’s Range― - ―
52-Week Range$0.16 - $1.89
Previous CloseN/A
Volume34.37K
Average Volume (3M)19.63M
Market Cap
$8.78M
Enterprise Value$514.34K
Total Cash (Recent Filing)$3.59M
Total Debt (Recent Filing)$34.52K
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Aug 18, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding25,478,170
10 Day Avg. Volume388,829
30 Day Avg. Volume19,627,089
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)29.75
Price to Sales (P/S)29.50
P/FCF Ratio-0.97
Enterprise Value/Market Cap0.06
Enterprise Value/Revenue1.44
Enterprise Value/Gross Profit1.56
Enterprise Value/Ebitda-0.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.5
Revenue Forecast (FY)$1.41M
Bulls Say, Bears Say
Bulls Say
Low LeverageNear-zero formal debt materially reduces interest burden and short-term default risk, giving the company structural financial flexibility. Over a 2–6 month horizon this lowers mandatory cash outflows and preserves options to negotiate better financing terms or equity raises when needed.
Solid Gross MarginA roughly 63% gross margin indicates favorable product or service economics at the unit level. This provides a durable foundation: if management can control operating spend or scale revenue, the company has structural room to improve profitability without major changes to core technology or pricing.
Leadership Continuity & RetentionMulti-year employment agreements for CEO and CFO (and formal R&D VP arrangements) reduce execution risk from leadership turnover. Stable management supports long-term R&D and financing strategies, improving the odds of consistent program execution and investor dialogue over multiple years.
Bears Say
High Cash BurnPersistent, large negative operating and free cash flow relative to a tiny revenue base forces reliance on external financing. Over months this creates dilution risk, constrains runway, and may force higher-cost funding or strategic tradeoffs that impair long-term R&D investment and commercialization timelines.
Tiny, Declining RevenueA very small and falling revenue base undermines operational sustainability: fixed R&D and SG&A costs far exceed sales. Structurally this signals weak commercial traction or timing delays, making it harder to scale, justify ongoing burn, or attract favorable financing without meaningful clinical or commercial milestones.
Debt Agreement And Board InfluenceThe one-year, high-cost (12%) loan and appointment of lender designees materially alters governance and increases financing costs. Structurally this can shift strategic priorities toward near-term liquidity and creditor protections, limiting flexibility for long-term R&D choices and potential strategic transactions.
BioRestorative Therapies News
BRTX FAQ
What was Biorestorative Therapies, Inc.’s price range in the past 12 months?
Biorestorative Therapies, Inc. lowest stock price was $0.16 and its highest was $1.89 in the past 12 months.
What is Biorestorative Therapies, Inc.’s market cap?
Biorestorative Therapies, Inc.’s market cap is $8.78M.
When is Biorestorative Therapies, Inc.’s upcoming earnings report date?
Biorestorative Therapies, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 38 days.
How were Biorestorative Therapies, Inc.’s earnings last quarter?
Biorestorative Therapies, Inc. released its earnings results on May 20, 2026. The company reported -$0.2 earnings per share for the quarter, the consensus estimate of -$0.2 by $0.
Is Biorestorative Therapies, Inc. overvalued?
According to Wall Street analysts Biorestorative Therapies, Inc.’s price is currently Overvalued.
Does Biorestorative Therapies, Inc. pay dividends?
Biorestorative Therapies, Inc. does not currently pay dividends.
What is Biorestorative Therapies, Inc.’s EPS estimate?
Biorestorative Therapies, Inc.’s EPS estimate is -0.1.
How many shares outstanding does Biorestorative Therapies, Inc. have?
Biorestorative Therapies, Inc. has 25,478,170 shares outstanding.
What happened to Biorestorative Therapies, Inc.’s price movement after its last earnings report?
Biorestorative Therapies, Inc. reported an EPS of -$0.2 in its last earnings report, expectations of -$0.2. Following the earnings report the stock price went down -7.65%.
Which hedge fund is a major shareholder of Biorestorative Therapies, Inc.?
Currently, no hedge funds are holding shares in BRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biorestorative Therapies, Inc.
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
Technical Analysis
Ownership Overview
1.46% Insiders
0.22% Mutual Funds
0.16% Other Institutional Investors
98.17% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---